Synapse - Hira Rizvi

Results (122)

Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC

Meeting Abstract

Arbour, K. C.; Mezquita, L.; Long, N.; Rizvi, H.; Auclin, E.; Ni, A.; Bernal, G. M.; Chaft, J. E.; Ferrara, R.; Lai, W. C. V.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Comparison of outcomes with PD-L1 tumor proportion score (TPS) of 50-74% vs 75-100% in patients with non-small cell lung cancer (NSCLC) treated with first-line PD-1 inhibitors

Meeting Abstract

Aguilar, E. J.; Rizvi, H.; Kravets, S.; Lydon, C. A.; Adeni, A. E.; Subegdjo, S.; Hellmann, M. D.; Awad, M. M.
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Derived neutrophil-to lymphocyte ratio (dNLR) change between baseline and cycle 2 is correlated with benefit during immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients

Meeting Abstract

Mezquita, L.; Arbour, K.; Auclin, E.; Saravia, D.; Rizvi, H.; Hendriks, L.; Planchard, D.; Park, W.; Nadal, E.; Ruffinelli Rodriguez, J. C.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

Concurrent mutations in STK11 and KEAP1 is associated with resistance to PD-(L)1 blockade in patients with NSCLC despite high TMB

Meeting Abstract

Arbour, K.; Shen, R.; Plodkowski, A.; Rizvi, H.; Ni, A.; Long, N.; Halpenny, D.; Sanchez-Vega, F.; Rudin, C.; Riely, G.; more...
Journal of Thoracic Oncology (2018)

Fulltext@MSK | Save

Efficacy and genomic correlates of response to anti-PD1/PD-L1 blockade in non-small cell lung cancers harboring targetable oncogenes

Meeting Abstract

Vokes, N.; Jimenez Alguilar, E.; Adeni, A.; Umeton, R.; Sholl, L.; Rizvi, H.; Hellmann, M.; Awad, M.; Van Allen, E.
Journal of Thoracic Oncology (2018)

Fulltext@MSK | Save

Clinical and molecular characteristics of EGFR mutant lung cancers with concurrent TP53 and RB1 mutations

Meeting Abstract

Offin, M.; Tenet, M.; Shen, R.; Rekhtman, N.; Rizvi, H.; Hellmann, M.; Arcila, M.; Ladanyi, M.; Rudin, C.; Kris, M.; more...
Journal of Thoracic Oncology (2018)

Fulltext@MSK | Save

Outcomes in NSCLC patients treated with first-line pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 50-89% vs 90-100%

Meeting Abstract

Jomenez Alguilar, E.; Gainor, J.; Kravets, S.; Khosrowjerdi, S.; Lydon, C.; Adeni, A.; Subegdjo, S.; Rizvi, H.; Hellmann, M.; Awad, M.
Journal of Thoracic Oncology (2018)

Fulltext@MSK | Save

Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non–small-cell lung cancer